Skip to main content




upgraded at Deutsche to Buy. $41.50 price target. Company has the cleanest fundamentals in the business. Expect little industry reform risk.



upgraded at Oppenheimer from Perform to Outperform. $8 price target. See little further dilution after the latest offering.

Image placeholder title

Fidelity National


upgraded at Oppenheimer. Rating raised to Outperform from Perform. Establishes price target of $25. Maintains 2009 EPS estimates of $1.61.

Illinois Tool Works


downgraded at BB&T from Buy to Hold. Valuation call, as sales are weak but stable.



downgraded at Morgan Joseph from Buy to Hold. Valuation call, with the stock reaching the $10 price target.

Quality Systems


downgraded at BB&T to Hold. Valuation call, as the stock is up 79% since December 3.


Advanced Micro Devices


estimates lowered at UBS. AMD loss estimates widened through 2010. Company seeing higher sales on improved PC trends, but is realizing higher loss from the Globalfoundries subsidiary. Neutral rating and $2.20 price target.



estimates raised at UBS through 2010. Bioscience division continues to be the main growth driver. Buy rating and $60 price target.

Bed, Bath & Beyond


numbers upped at Barclays to $27. Estimates also increased, following an upbeat meeting with management. Equal-weight rating.

Biogen Idec


estimates, target raised at Barclays to $40. Estimates also raised to reflect lower tax rates. Underweight rating.

Crown Holdings


numbers raised at UBS to $29. Estimates also increased, because of improved operating efficiency. Buy rating.

Cypress Semi


estimates lowered at UBS through 2010. Company realizing better sales, but is facing higher stock compensation costs. Neutral rating and $7 price target.

Cypress Semi


numbers increased at Barclays to $9. Estimates also raised, to reflect higher sales demand. Overweight rating.



estimates raised at Barclays through 2010, Barclays Capital said. Company is seeing leverage on cost controls. Overweight rating and $460 price target.

Intuitive Surgical


estimates raised at Morgan Stanley through 2010. Company posted a strong quarter, and the buyback program helped to boost earnings. Equal-weight rating.



estimates, target raised at Barclays through 2010. Company is selling more handsets and visibility is improving. Overweight rating and new $17 price target.

Parker Hannifin


estimates reduced at UBS through 2010. Demand remains weak, with little visibility for a turnaround. Neutral rating and $39 price target.

Sprint Nextel


estimates upped at Morgan Stanley through 2011. Company is seeing growth in pre-paid subscribers, though contract customers continue to fall. Underweight rating and $1 price target.



estimates raised at UBS; loss estimates improved. Company realizing higher average selling prices. Neutral rating and $11.50 price target.



target raised at Merrill/BofA to $12.50. Stock continues to trade with buyout rumors. Neutral rating.

This article was written by a staff member of